Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Carolina Holmén"'
Autor:
Anna Fogdell-Hahn, Tomas Olsson, Robert Movérare, Carolina Holmén, Jan Hillert, Elin Engdahl, Malin Lundkvist
Publikováno v:
Multiple Sclerosis Journal. 19:757-764
Background: A small proportion of multiple sclerosis (MS) patients treated with natalizumab develop anti-drug antibodies. Objective: The objective of this paper is to characterize the anti-natalizumab antibody response and to investigate differences
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3fff145ddab7803658e889276b85f45
https://doi.org/10.1177/1352458512462920
https://doi.org/10.1177/1352458512462920
Autor:
Malin Lundkvist, Charlotte Dahle, Anna Fogdell-Hahn, Jan Hillert, Jan Lycke, Petra Nilsson, Fredrik Piehl, Tomas Olsson, Nils Feltelius, Anders Svenningsson, Elin Karlberg, Carolina Holmén
Publikováno v:
Multiple Sclerosis Journal. 17:708-719
Background: A post marketing surveillance study was conducted to evaluate safety and efficacy of natalizumab in Swedish multiple sclerosis (MS) patients since its introduction in August 2006 until March 2010. Methods: Patients were registered in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3f351288c89b257e53c9bad795f2eaf
https://doi.org/10.1177/1352458510394701
https://doi.org/10.1177/1352458510394701
Publikováno v:
American Journal of Respiratory Cell and Molecular Biology. 32:18-27
The vast heterogeneity of endothelial cells (EC) in various organs necessitates isolation of EC from the relevant organs when defining mechanisms of site-specific pathologies. We report a novel finding that describes the presence of two heterogeneous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ba029399e7a2892b1a7771dff7b5a9c
https://doi.org/10.1165/rcmb.2004-0253oc
https://doi.org/10.1165/rcmb.2004-0253oc
Autor:
Grzegorz Nowak, Mehmet Uzunel, Carolina Holmén, Kjell Hultenby, Azza Karrar, S. Nava, Suchitra Sumitran-Holgersson
Publikováno v:
Circulation. 110:3699-3707
Background—Receptor tyrosine kinases that include vascular endothelial growth factor (VEGFR)-1, VEGFR-2, and Tie-2 regulate cardiovascular development and physiological and pathological angiogenesis. We were interested in the phenotypic and functio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82d3dc8b450a2653a0c9d9e7914ec8b9
https://doi.org/10.1161/01.cir.0000143626.16576.51
https://doi.org/10.1161/01.cir.0000143626.16576.51
Autor:
Verena I. Leussink, Kathleen Wolfram, Ryan Ramanujam, Nina Nordin, Thomas Dehmel, Carolina Holmén, Tomas Olsson, Clemens Warnke, Bernd C. Kieseier, Hans-Peter Hartung
Publikováno v:
Neurology. 83(23)
Objective: To assess whether pretreatment-lymphocyte counts, treatment before fingolimod, age, sex, or body mass index (BMI) affects the risk of fingolimod-induced lymphopenia in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70a9c77728999504068a36320671e4f7
https://pubmed.ncbi.nlm.nih.gov/25361781
https://pubmed.ncbi.nlm.nih.gov/25361781
Autor:
Fredrik Piehl, Henrik Matell, Anders Svenningsson, Jan Hillert, Jan Lycke, Mohsen Khademi, Carolina Holmén, Tomas Olsson
Publikováno v:
Multiple sclerosis (Houndmills, Basingstoke, England). 21(1)
Background: Natalizumab is approved for treatment of active forms of relapsing–remitting multiple sclerosis (MS) based on a pivotal phase III study comprising patients aged 18–50 years. The effect of natalizumab has not been specifically studied
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9c382c06109a836499fd5859be53fdf
https://pubmed.ncbi.nlm.nih.gov/24866201
https://pubmed.ncbi.nlm.nih.gov/24866201
Autor:
Bernd C. Kieseier, Meena Subramanyam, Carolina Holmén, Tatiana Plavina, Ingrid Kockum, Tomas Olsson, Tomas Bergström, Jan Hillert, Anna Fogdell-Hahn, Clemens Warnke, Susan Goelz, Afsar Rahbar, Ryan Ramanujam
Publikováno v:
Journal of Neurology, Neurosurgery, and Psychiatry
Background The anti-JC virus (JCV) antibody status has been introduced to stratify patients with multiple sclerosis (MS) for higher or lower risk of progressive multifocal leukoencephalopathy (PML). Objective To assess the potential utility of anti-J
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58a45ace65a6f0ce83e6c66156c0ddf2
https://pubmed.ncbi.nlm.nih.gov/23606737
https://pubmed.ncbi.nlm.nih.gov/23606737
Publikováno v:
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 31
A post-marketing surveillance program was implemented to monitor the safety and open label efficacy of natalizumab since its launch in Sweden August 2006. Patients are registered in the Swedish multiple sclerosis (MS)-registry that has a nationwide c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65a96a4a63e3ee329768780d92bdb75b
https://pubmed.ncbi.nlm.nih.gov/20556456
https://pubmed.ncbi.nlm.nih.gov/20556456
Autor:
Elzafir Elsheikh, Carolina Holmén, Abdul Rashid Qureshi, Sirpa Jalkanen, Suchitra Sumitran-Holgersson, Marta Christensson, Anne-Sofie Johansson, Jining Liu
Publikováno v:
Journal of the American Society of Nephrology : JASN. 18(9)
The pathogenic role of anti-endothelial cell antibodies (AECA) in vascular injury is debated. It was previously shown that many patients with Wegener's granulomatosis (WG) have AECA that react with human kidney microvascular endothelial cells (EC). I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baba682a4adc645152fff676ed605d0b
https://pubmed.ncbi.nlm.nih.gov/17724231
https://pubmed.ncbi.nlm.nih.gov/17724231
Autor:
Bengt Lindholm, Suchitra Sumitran-Holgersson, Ernesto Rodríguez-Ayala, Qiang Yao, Carolina Holmén, Peter Stenvinkel
Publikováno v:
Blood purification. 24(2)
Background: Patients with chronic kidney disease (CKD) display endothelial dysfunction and are at a high risk for atherosclerotic cardiovascular disease (CVD). Recent studies suggest that circulating detached endothelial cells (CECs) and stimulated e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::899541564d58e6d8a981f26265f4068a
https://pubmed.ncbi.nlm.nih.gov/16373998
https://pubmed.ncbi.nlm.nih.gov/16373998